Method for producing antigen-specific T lymphocytes
Through monoclonal antibody labeling and sorting technology, antigen-specific T lymphocyte method is used to solve the multispecific and stability problems in Treg lymphocyte treatment, achieving efficient targeting and inhibition of specific antigens, and improving the treatment Accuracy and effectiveness.
Patent Information
- Application Number
- CN202080059223.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-08-22
- Filing Date
- 2020-08-24
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-08-24
AI Technical Summary
Among the existing Treg lymphocyte treatment methods, the effectiveness of multispecific products is limited and it is difficult to target specific antigens, resulting in poor treatment effects and it is difficult to maintain cell stability and inhibitory activity during the amplification process, affecting clinical application. .
Antigen-specific T lymphocytes were stimulated by antigen-loaded autologous monocytes using monoclonal antibody-labeled autologous monocytes, labeled with fluorescent dyes and gamma-ray irradiation, combined with anti-CD154 Anti-CD28 antibodies were co-cultured to proliferate and sort out antigen-specific T lymphocytes, and their activity was evaluated using low-intensity fluorescent markers.
Improve the antigen specificity and inhibitory activity of Treg lymphocytes, enhance the response ability to specific antigens, reduce systemic side effects, improve the accuracy and effectiveness of treatment, reduce the therapeutic dose, and maintain the stability of the cells and Suppression function.
Smart Images

Figure CN114269905B_ABST
Abstract
Description
[0001] The present invention relates to a method for manufacturing antigen-specific T lymphocytes (CellTrAg) for their clinical use in immunotherapy. CellTrAg produced in this manner is suitable for treating autoimmune diseases, including, for example, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, and for inhibiting adverse immune responses such as transplant rejection, allergic reactions and graft-versus-host disease (GVHD).
[0002] Treg lymphocytes make up approximately 1% of all peripheral blood lymphocytes but are important for maintaining tolerance to their own tissues (Trzonkowski P 2009)(Vignali DA 2008)(Yi S 2012). The absence of regulatory T cells leads to many autoimmune diseases and hypersensitivity reactions, as seen in patients with X-linked immunodeficiency syndrome, polyendocrinopathy and enteropathy (IPEX) (Gambineri E 2003). Treg lymphocytes can be called "intelligent steroids" because, as steroids, they suppress inflammatory responses and exert immunosuppressive effects, while in contrast, the physiological suppressive effects of Treg cells only involve pathological reactions (such as those against their own tissues). Results of clinical trials, including our observations, indicate that Treg lymphocyte therapy is safe and does not impair immune responses against foreign dangerous antigens (viruses, bacteria, cancer cells) (Marek-Trzonkowska N 2012)(Marek-Trzonkowska N 2014)(Martelli MF 2014)(Bluestone JA 2015).
[0003] Our research team has been studying the biology and clinical applications of Treg lymphocytes for more than 10 years. We were the first to use ex vivo expanded Treg cells to treat graft versus host disease (GvHD) in adults (NKEBN / 458-310 / 2008)(Trzonkowski P 2009) and in children with type 1 diabetes (T1D) (TregVAC ISRCTN06128462; TregVAC2.0EudraCT:2014-004319-35)(Marek-Trzonkowska N 2012)(Marek-Trzonkowska N 2014) and multiple sclerosis (TregSM EudraCT:2014-004320-22)(Trzonkowski P 2015). Currently, clinical trials using Treg cells are also being conducted in other centers around the world, involving the treatment / prevention of GVHD (Di Ianni M 2011), the treatment of T1D in adults (NCT01210664), and the induction of tolerance in kidney transplantation (NCT02091232 and NCT02129881) and liver (ThRIL NCT02166177 and NCT01624077). In recent years, the dynamic development of cell therapy using Treg lymphocytes as a therapeutic tool has begun. Currently, there are about 40 clinical trials being conducted around the world using these cells. All of these projects are guided by one goal, namely, smart immunosuppression, which will suppress unwanted immune responses without impairing physiological immune responses (Trzonkowski P 2015, Gliwiński M 2017).
[0004] In the above studies, Treg lymphocytes were taken from peripheral blood or umbilical cord blood units of patients. The best isolation method is to use a sorter, which will produce a very pure (97-100%) population of these cells. Typically, lymphocytes with a CD3+CD4+CD25high phenotype or a CD3+CD4+CD25highCD127 phenotype or a CD3+CD4+CD25highCD127low phenotype are isolated (Application P.399447)(Trzonkowski P 2009)(Marek-Trzonkowska N 2012)(Marek-Trzonkowska N 2014)(Trzonkowska P 2015). The isolated cells are then activated for 10-14 days of strong proliferation to obtain a sufficient amount for administration to patients. Effective expansion must be carried out under conditions that maintain the complete phenotype (especially including high expression of the FoxP3 factor), which depends on the specific laboratory activities (Marek N 2011, K 2013, Marek-Trzonkowska N 2017). Moreover, since Treg lymphocyte preparations are classified as advanced therapy medicinal products (ATMPs) and are regulated by the Pharmaceuticals Act and Regulation (EC) No 1394 / 2007 of the European Parliament on advanced therapy medicinal products, such expansion in clinical applications must be performed according to Good Manufacturing Practice (GMP) standards.
[0005] The use of cells produced according to the above scheme means that they are multi-specific - it is a group of lymphocytes that are specific to many different antigens, so their effectiveness after administration is limited. Of course, the high efficiency of multi-specific (polyclonal) products is affected by the fact that all Treg lymphocytes have tropism for inflammatory sites, the ability to regulate "bystander" types, and the ability to convert other cells into regulatory phenotypes on the basis of infection tolerance. However, the effectiveness of such products can be improved by targeting cells to specific antigens. In this way, such antigen-specific Treg lymphocytes can only migrate to the site where such antigen expression occurs and selectively inhibit the activity of pathological effector cells that recognize such antigens only at the site of the inflammatory response caused by such antigen stimulation. In the case of autoimmune diseases, the destruction of affected organs (for example, insulin-producing pancreatic islets in type 1 diabetes or myelin sheaths in multiple sclerosis) can be inhibited. At the same time, it will limit the systemic side effects of Treg lymphocytes, which will not surround the entire lymphatic system and will only show tropism to sites expressing specific antigens to which they are sensitive.
[0006] The development of a safe, easy-to-use, and economically feasible method to expand stable Treg lymphocytes with specific antigen specificity and high suppressive potential is crucial for the development and success of clinical trials using Treg cells as a therapeutic tool.
[0007] Another problem seems to be an excessive immune response, also known as hypersensitivity to allergens. Most of these diseases are successfully treated symptomatically with existing drugs. However, some forms of hypersensitivity reactions can lead to serious complications that can cause disability or even death. The disease process usually progresses over time, inflammation increases, leading to permanent structural changes in the airways, and the drugs used are no longer effective (Panettieri RA Jr 2008)(Barbaro MP 2014). In this case, antigen-specific Treg lymphocytes may also become a modern anti-allergic drug.
[0008] In summary, safe and effective drugs for the treatment of autoimmune diseases, allergies and transplant recipients are those that maximally selectively modulate the immune system's response to well-defined antigens responsible for unwanted immune reactions (e.g., autoimmune diseases or allergies, rejection of organs, graft-versus-host disease) while leaving the physiological immune response to foreign and dangerous antigens unimpaired. The opportunity for such intelligent immunosuppression is precisely antigen-specific Treg lymphocytes. However, a condition for the success of clinical therapy with Treg cells is the development of a patient-safe protocol to expand these lymphocytes, which will guarantee a large number of antigen-specific cells while maintaining their stability and suppressive activity throughout the culture process (Tang Q 2013). The method described in this patent application meets the above requirements.
[0009] Specifically, the present invention provides a method for preparing antigen-specific T lymphocytes labeled and sorted with a monoclonal antibody, wherein the lymphocytes:
[0010] a) by using autologous monocytes loaded with antigen;
[0011] b) suspending the regulatory T lymphocytes or effector T lymphocytes to be produced in PBS and staining the cells with a fluorescent dye;
[0012] c) then incubating the lymphocytes in the dark;
[0013] d) The lymphocytes are then vigorously washed several times with culture medium;
[0014] e) regulatory T lymphocytes or effector T lymphocytes stained with intracellular fluorescent dyes are suspended in a culture medium containing antigen-loaded gamma-irradiated autologous CD14+ monocytes;
[0015] f) incubating the co-culture of regulatory T lymphocytes or effector T lymphocytes and CD14+ monocytes with anti-CD154 and anti-CD28 antibodies;
[0016] g) incubating the co-culture in a culture medium; and
[0017] h) After incubation, antigen-specific T lymphocytes are sorted based on low-intensity intracellular dye fluorescence, which is a marker for antigen specificity, since loss of fluorescence correlates with proliferation intensity.
[0018] In the method as defined above, preferably the regulatory T lymphocytes or effector T lymphocytes are suspended at the following concentrations: 1×10 6 cells / ml PBS.
[0019] In the method as defined above, preferably the lymphocytes are stained with one of the following fluorescent dyes: CFSE or Violet Blue at a final concentration of 1-5 μM.
[0020] In the method as defined above, the lymphocytes are preferably incubated at room temperature or 37°C for 20 minutes.
[0021] In the method as defined above, preferably autologous monocytes are added to the co-culture in a final ratio of monocytes:lymphocytes of 1:1.
[0022] In the method as defined above, preferably the monocytes are irradiated with gamma rays.
[0023] In the method as defined above, preferably the co-culture of monocytes and lymphocytes is incubated with an anti-CD154 antibody at a final concentration of 5 μg / ml and an anti-CD28 antibody at a final concentration of 5 μg / ml.
[0024] In the method as defined above, preferably the co-culture is incubated at 37°C in 5% CO2.
[0025] In the method as defined above, the specificity for the antigen is preferably assessed in a functional test in which antigen-specific T lymphocytes, in particular T lymphocytes sorted on the basis of a low fluorescence of an intracellular dye, are more active than non-specific T lymphocytes, in particular T lymphocytes sorted on the basis of retention of a high fluorescence of the intracellular dye, wherein, in the case of regulatory T lymphocytes, activity is defined as inhibition of effector T lymphocyte function, and in the case of effector T lymphocytes, activity is defined as increased proliferation intensity and increased production intensity of cytokines and cytotoxic factors. Description of the drawings:
[0026] Figure 1 – The experimental protocol is presented. Buffy coats were separated into monocytes and lymphocytes. Lymphocytes were sorted into regulatory T cells (Treg) and effector T cells (Eff), stained with CFSE and stimulated with irradiated monocytes preloaded with peptides (insulin or peptide 9-23). Polyclonal Treg and Eff were generated using anti-CD3 / anti-CD28 beads. After 7 days of co-culture, cells were cultured using Figure 2 The scheme shown in C and 2D, cells were sorted into antigen-specific and nonspecific cells based on the dilution fluorescence of CFSE. The obtained Treg polyclones (Treg poly ), antigen-specific (Treg spec ) and nonspecific (Treg unspec ) subset, where the responder is an autologous effector T cell stained by Violet, regardless of whether the autologous effector T cell is polyclonal (Eff poly) or antigen-specific (Eff spec ). Eff was prepared by stimulating monocytes preloaded with antigen. spec .
[0027] Figure 2 – The method for antigen-specific regulatory T cell sorting is presented. To distinguish Tregs from other cells (A), in particular from antigen-presenting monocytes used during stimulation, they are stained with fluorescent dyes (B). After the co-culture, Treg lymphocytes that recognize the antigens arrayed in the fluorescence-reduced field (P1 gate) are sorted into separate antigen-specific populations.
[0028] Figure 3 – The percentage of Tregs responding to antigen in co-cultures with monocytes is shown. The analysis covers Treg cells co-cultured with monocytes presenting antigen (insulin or peptide 9-23). In some cultures, monoclonal antibodies anti-CD28 and anti-CD154 (mabs28 / 154) were added to provide a second signal. The percentage of proliferative (antigen-specific) Tregs (A) and the percentage of proliferative (light blue) or non-proliferative (dark blue) Tregs expressing high intensity FoxP3 expression (high) and proliferative (light blue) or non-proliferative (dark blue) Tregs (B) were assessed. Results are expressed as mean + / - SD. The dot plot in Figure C shows an example of the analysis of co-cultures stimulated with monocytes loaded with insulin, and the dot plot in Figure D shows an example of the analysis of co-cultures stimulated with monocytes loaded with peptide 9-23. The gate of CD4 to Violet in the dot plot shows proliferative (SPEC) antigen-specific Tregs on the left and non-proliferative (UNSPEC) non-specific Tregs on the right. Arrows link to the corresponding dot plots showing FoxP3 expression. The upper gate represents cells with FoxP3 high subpopulation, the lower gate represents FoxP3 low Subgroup.
[0029] Figure 4– Demonstration of Treg lymphocyte clonality. The clonality of Treg lymphocytes was measured by the expression of a single class of TCR receptors (Vβ chain). Examples of Treg lymphocyte clonal analysis before culture (‘Treg POLY’) and after co-culture with monocytes presenting antigen (insulin or 9-23 peptide), after which Treg lymphocytes were sorted according to their proliferation capacity: proliferating cells (‘Treg SPECIFIC’) and non-proliferating cells (‘Treg UNSPECIFIC’). On the arrows, clones were identified as preferentially stimulated to proliferate during co-culture (clearly increased percentage relative to ‘Treg POLY’ after co-culture). In each of the cultures performed, there were clones with different Vβ expressions, with no more than one or two clones preferentially increasing in each culture and growing by no more than a few percent.
[0030] Figure 5 -Show functional test-inhibition of effector T lymphocyte proliferation.Generated Treg subgroups (Tregs), such as polyclonal (Tregs POLY) cells, cells with antigen-specific (Treg SPEC) to insulin or peptide 9-23, and non-specific (Treg UNSPEC) cells are co-cultured with autologous effector T cells (Effector) in the ratio given at the bottom of the figure.Effector cells are considered as responders, whether the effector cells are polyclonal (upper chart A) or antigen-specific (lower chart B).Then co-cultures are stimulated with irradiated monocytes preloaded with insulin or peptide 9-23.Reading is the inhibition of the proliferation of responders.The result is indexed only according to the culture of responders, and its proliferation is always considered as 100%.The results are shown as mean + / -min.-max.Significant differences are marked with / * and p values.
[0031] Figure 6 -Show the inhibition (ELISA) of the production of IFNγ by functional test-effector T lymphocytes.Generated Treg subgroups (Tregs), such as polyclonal (Tregs POLY) cells, cells with antigen-specific (Treg SPEC) to insulin or peptide 9-23 and non-specific (Treg UNSPEC) cells and autologous effector T cells (Effector) are co-cultured with the ratio given at the bottom of the figure.Effector cells are regarded as responders, whether the effector cells are polyclonal (upper chart A) or antigen-specific (lower chart B).Then co-cultures are stimulated with irradiated monocytes preloaded with insulin or peptide 9-23.Reading is the inhibition of the production of IFNγ by responders.Results are only indexed according to the culture of responders, and their proliferation is always regarded as 100%.Results are shown as mean + / -min.-max.Significant differences are marked with / * and p value.
[0032] Figure 7 -Show the inhibition-ELISPOT of the production of IFNγ by functional test-effector T lymphocytes.Generated Treg subgroups (Tregs), such as polyclonal (Tregs POLYclonal) cells, cells with antigen-specific (Treg SPECific) and non-specific (Treg UNSPECific) cells to insulin or peptide 9-23 are co-cultured with the autologous effector T cells as responders, whether the autologous effector T cells are polyclonal or antigen-specific.Treg and effector cells are co-cultured with the ratio given at the top of the figure.Then co-cultures are stimulated with irradiated monocytes preloaded with insulin or peptide 9-23.Reading is the inhibition of the production of IFNγ by responders.The results are shown as pictures of the culture and spot number in specific wells.
[0033] The present invention is illustrated by the following examples, but is not limited thereto.
[0034] Materials and methods
[0035] An overview of the methods and functional analyses is given in Figure 1 shown.
[0036] Blood Donors
[0037] Buffy coats were obtained from the Regional Blood Donation and Treatment Centre in Gdańsk.
[0038] B:9-23 insulin peptide and insulin
[0039] B:9-23 insulin peptide was synthesized at Lipopharm (Gdansk, Poland) as a white powder with a purity of >90% using HPLC method. The peptide was dissolved in deionized autoclaved water at a final concentration of 0.5 μg / μl and stored at -70°C for no longer than 3 months.
[0040] The insulin used in the test was commercially available ( Novo Nordisk A / S) and stored in a refrigerator at 2-8°C.
[0041] Cell isolation and sorting
[0042] Regulatory T cells and effector T cells
[0043] Figure 2An overview of cell preparation and sorting is presented. Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained from healthy volunteer blood donors by Ficoll-Hypaque gradient centrifugation and used freshly. Tregs and Teffs were freshly isolated according to our previously described protocol. Briefly, CD4+ T cells were isolated by negative selection using the EasySep Human CD4+ T Cell Enrichment Kit (Stemcell Technologies) according to the manufacturer’s instructions. + T cells. Subsequently, CD4 + T cells were stained with monoclonal antibodies (mAbs) specific for the following antigens: CD3, CD4, CD25, and CD127. Then, cells were sorted into the following phenotypes using a FACSAriaIIu sorter (BD Biosciences, USA): Treg: CD3 + CD4 + CD25 High CD127 - / Low lin - doublet - , and Teffs:CD3 + CD4 + CD25 - CD127 High lin - doublet - Isolated Treg lymphocytes and Teff cells were cultured on separate plates and incubated at 37°C in GMP-compliant medium X-VIVO20 (Lonza). The medium was supplemented with heat-inactivated human AB serum (10%), interleukin 2 (IL-2; 2000 U / ml; Proleukin; Chiron, San Diego, CA), penicillin (100 U / ml), and streptomycin (100 mg / ml) for 24 h.
[0044] Monocytes
[0045] Use EasySep according to the manufacturer's instructions. TM Human CD14 Positive Selection Kit II (StemCell Technologies) was used to isolate autologous CD14+ cells by positive selection with a purity of more than 95%. The isolated monocytes (10 6 Cells were cultured in the GMP-compliant medium X-VIVO20 (Lonza) at 37°C. The previously prepared peptide solution (25 μg / well / ml) or insulin (100 μl / well / ml) was added for 24 hours. We prepared three conditions: monocytes were treated with B:9-23 insulin peptide (Mo9-23 ), insulin (Mo INS ) to stimulate or no stimulation (Mo).
[0046] Dye labeling and cell expansion
[0047] Monocytes
[0048] After 24 h of incubation, mononuclear cells were collected from the wells and irradiated with gamma rays (under standard conditions as for irradiation of blood preparations), counted, and expressed as 1×10 6 The cells were resuspended in fresh culture medium (X-VIVO20) at a final concentration of 10 cells / ml.
[0049] Treg cells and Teff cells
[0050] 24 hours after sorting, regulatory T lymphocytes were collected from the wells and washed with PBS to remove serum that would affect staining. The cells were then plated at 1 × 10 6 The cells were resuspended in PBS at a concentration of 10 cells / ml and stained with CFSE (Cell Trace CFSE Cell Proliferation Kit, Life Technologies) at a final CFSE concentration of 1 μM to 5 μM. The cells were incubated at 37°C in the dark for 20 minutes and then washed several times with PBS followed by culture medium (X-VIVO20+10% serum+penicillin / streptomycin). Effector T cells were also stained in a similar manner.
[0051] Alternatively, both lymphocyte populations were stained with Violet (Cell Trace Violet Cell Proliferation Kit, Life Technologies) at a final concentration of 1 μM to 5 μM in the manner described above.
[0052] Staining controls were performed on a flow cytometer (Fortessa, BD Bioscience).
[0053] Polyclonal stimulation
[0054] After the staining step, some of the cells were suspended in fresh culture medium (X-VIVO20, Lonza) containing 10% human inactivated serum and antibiotics penicillin / streptomycin (Sigma Aldrich). Next, the cells were seeded in 96-well plates (1×10 5 cells / well) and stimulated with magnetic beads coated with anti-CD3 and anti-CD28 antibodies (Treg Expansion Kit, Miltenyi Biotech) at a 1:1 ratio (beads: cells) and cultured for 7 days. We prepared two polyclonal cell conditions—Treg POLY and Teff POLY .
[0055] Antigen stimulation
[0056] After the staining step, some of the cells were suspended in fresh culture medium (X-VIVO20, Lonza) containing 10% human inactivated serum and the antibiotics penicillin / streptomycin (Sigma Aldrich). Next, the cells were seeded in 96-well plates (1×10 5 cells / well) and loaded with antigen (B: 9-23 insulin peptide (Mo 9-23 ) or insulin (Mo INS )) were stimulated with monocytes at a 1:1 ratio (Mo:cells). Subsequently, sterile anti-CD154 (purified NA / LE mouse anti-human CD154; BD Biosciences) and anti-CD28 (purified NA / LE mouse anti-human CD28; BD Biosciences) were added to the co-culture at a final concentration of 5 μg / ml. The prepared co-cultures were incubated at 37°C in 5% CO2 medium (X-VIVO20 + 10% serum + penicillin / streptomycin). We prepared two cell conditions - Treg 9-23 / INS+CD28CD154 and Teff 9-23 / INS+CD28CD154 At the same time, we prepared Treg cells loaded with antigen but without anti-CD28 and anti-CD154. 9-23 / INS and Teff 9-23 / INS As negative control, we used cells without monocytes (unstimulated, nonproliferated). As positive control, we used polyclonal cells (index POLY). Cells were cultured for 7 days.
[0057] Sorting of antigen-specific cells
[0058] On the 7th day of amplification, cells were collected and washed with fresh medium (X-VIVO). Cells were sorted using a FACS AriaIIu sorter (BD Biosciences, USA), and sorted by SSC-A dot plots (side scatter) relative to the 488nm channel for the Cell Trace CFSE cell proliferation kit (LifeTechnologies), or by SSC-A relative to the 450nm channel for the Cell Trace Violet cell proliferation kit (Life Technologies). In response to antigens presented by monocytes, proliferating cells (index PRO) were identified as cells with lower fluorescence than negative control cells [the sorting gate cutoff value was assumed to be a fluorescence intensity lower than the negative control peak, and the target contained no more than 5% of the negative control peak events with the lowest fluorescence]. Non-proliferating cells (index NON) refer to cells whose fluorescence is comparable to that of cells from the negative control [the sorting gate is assumed to be the fluorescence intensity of the negative control peak, and the target contains no less than 80% of the negative control peak events]. The obtained cells were either subjected to quality control (phenotypic control, functional tests for inhibition of proliferation and interferon-γ production) or further cultured by adding magnetic microspheres coated with anti-CD3 and anti-CD28 (Miltenyi Biotec) antibodies in a 1:1 ratio (cells:beads) to obtain as many antigen-specific regulatory T lymphocytes as possible.
[0059] Quality Control
[0060] Phenotypic examination
[0061] On day 7 of expansion, samples of Tregs and Teffs were labeled with Abs against the following antigens (Ag): CD4, CD25, CD127, CD45RA (BD Biosciences, USA), CD62L (Life Technologies, USA), Foxp3 (using Foxp3 staining buffer kit (eBioscience, USA)) and analyzed by flow cytometry (Fortessa, BD Biosciences, USA).
[0062] Proliferation inhibition assay
[0063] On the 7th day of expansion, we performed a functional assay to inhibit the production of interferon-γ (IFN-γ). Treg and Teff cells were washed with PBS buffer, purified from the microspheres used for stimulation by a magnet and counted. The cells were then resuspended in fresh culture medium containing antibiotics and human heat-inactivated human AB serum (10%). For the next two days, cells from each condition were still cultured separately. No IL-2 and activated microspheres were added during this period. After 48 hours, Teff cells were washed with PBS buffer and counted. Teff cells were stained with CFSE (Cell Trace CFSE Cell Proliferation Kit, LifeTechnologies, 1 μM, 15 minutes, 37°C) or Violet (Cell Trace Violet Cell Proliferation Kit, LifeTechnologies, 1 μM; 15min, 37°C) to analyze their proliferation in the presence of Treg lymphocytes. Dye selection is determined by previous Treg lymphocyte staining-if Treg is stained with CFSE, Teff cells are stained with Violet, and vice versa.
[0064] Labeled autologous Teff cells (responders) and Treg cells (specific, nonspecific, and polyclonal) were mixed in the following ratios: 1:1, 1: 1 / 2, 1: 1 / 4 and 1: 1 / 8. The number of Teff cells was constant each time, while the number of Treg lymphocytes was variable. The cells were suspended in fresh culture medium containing heat-inactivated human AB serum (10%), interleukin 2 (IL-2; 100 U / ml) and antibiotics (penicillin (100 U / ml) and streptomycin (100 mg / ml)). As stimulators, we used antigen-loaded (Mo 9-23 Or Mo INS ) of irradiated autologous monocytes, which were added to Teff at a 1:1 ratio. As a positive control, we used mononuclear cells (Mo 9-23 Or Mo INS ) stimulated Teff (without Treg cells) or microspheres coated with anti-CD3 and anti-CD28 antibodies. As a negative control, we used unstimulated Teff cells (reference cytometer readings). Another control was unstained Treg cells cultured in the absence of Teff cells.
[0065] The cells were cultured in culture medium (X-VIVO20 + 10% serum + p / s) at 37 ° C in 5% CO2 for 6 days. Thereafter, the cells were collected and analyzed using a flow cytometer (Fortessa, BD Biosciences). Unstimulated Teff cells cultured in the absence of Treg cells were used as background and used as 100%, which means that 100% of the cells did not divide. Stimulated Teff cells cultured in the absence of Treg cells were used as 0%, which means that proliferation was not inhibited.
[0066] Teff cells cultured with Treg cells inhibit INF-γ production
[0067] Treg lymphocyte samples from each culture condition were collected for functional testing to confirm the inhibitory effect of Treg cells on the secretion of IFN-γ by autologous Teff cells. At the same time, Teff lymphocyte samples, which were previously expanded under the same conditions as the tested Treg, were collected as responders in the proliferation inhibition assay. In this way, two series of tests were performed as responders: polyclonal Teff (Teff POLY ) and antigen-specific (proliferative) Teff (Teff 9-23_PRO or Teff INS_PRO ).
[0068] The cells to be tested (Treg and Teff) were washed with PBS, purified from the microspheres used for stimulation and counted. Next, the cells were suspended in fresh culture medium containing heat-inactivated human AB serum (10%) and antibiotics (penicillin / streptomycin). In the next two days, cells from each condition were still cultured separately. IL-2 and activated microspheres were not added during this period.
[0069] Labeled autologous Teff cells (responders) were mixed with Treg cells in the following ratios: 1:1, 1:1 / 2, 1:1 / 4, and 1:1 / 8. The number of Teff cells was constant each time, while the number of Treg lymphocytes was variable. The cells were suspended in fresh culture medium containing heat-inactivated human AB serum (10%), interleukin 2 (IL-2; 100 U / ml), and antibiotics (penicillin (100 U / ml) and streptomycin (100 mg / ml)). As stimulators, we used antigen-loaded (Mo 9-23 Or Mo INS ) of irradiated autologous monocytes, which were added to Teff at a 1:1 ratio. As a positive control, we used mononuclear cells (Mo 9-23 Or Mo INS) stimulated Teff (without Treg cells) or microspheres coated with anti-CD3 and anti-CD28 antibodies. As a negative control, we used unstimulated Teff cells (reference cytometer readings). Another control was unstained Treg cells cultured in the absence of Teff cells.
[0070] The cells were cultured in culture medium (X-VIVO20 + 10% serum + p / s) at 37°C in 5% CO2 for 6 days. Thereafter, the supernatant was harvested from the culture medium and the IFN-γ level was determined by ELISA according to the manufacturer's instructions (Human IFN-γ OptEIA Kit II, BD Biosciences).
[0071] INF-γ–ELISpot
[0072] The co-culture of Teff lymphocytes (responders) and Treg lymphocytes was cultured on a special ELISpot plate for 48 hours. This method can accurately determine how many cells produce cytokines (INF-γ). After incubation, the cells on the plate are washed and the plate is stained according to the manufacturer's instructions (MABtech). Reading is performed in an ELISPOT plate reader (Immunospot 5, CTL).
[0073] result
[0074] Obtaining the effectiveness of antigen-specific regulatory T cells stimulated with antigen-displaying monocytes and anti-CD28 and anti-CD154 antibodies
[0075] Analysis of the percentage of Tregs (i.e., antigen-specific regulatory T cells) generated by autologous antigen-presenting monocytes showed that the proliferation of these cells was higher when anti-CD28 and anti-CD154 antibodies were added to the co-cultures, especially for co-cultures with insulin (t-test difference without antibody / added antibody: insulin p=0.041, peptide 9-23 p=0.044). Figure 3 A)
[0076] Comparing the effect of the peptides used on the proliferation of Tregs generated by autologous antigen-presenting monocytes, we have shown that the presented peptide 9-23 significantly more strongly increased the percentage of these cells in cultures without anti-CD28 and anti-CD154 antibodies than insulin (t-test p=0.032). The use of anti-CD28 and anti-CD154 antibodies in co-culture resulted in similar percentages of proliferating Treg lymphocytes in both cohorts (t-test p=0.54).
[0077] Figure 3 C, 3D shows the dot plot example and analysis method.
[0078] Expression of FoxP3 transcription factor by antigen-specific regulatory T lymphocytes stimulated with antigen-presenting monocytes and anti-CD28 and anti-CD154 antibodies
[0079] The percentage of lymphocytes expressing FoxP3 was not less than 90% in all cultures throughout the experiment.
[0080] For antigen-specific / proliferative populations, the percentage of Treg cells showing high expression of FoxP3 transcription factor (i.e., CD3+CD4+CD25highCD127-FoxP3high phenotype) stimulated by autologous antigen-presenting monocytes was significantly higher compared to the corresponding nonspecific / non-proliferative Treg lymphocytes (all t-tests p<0.05) ( Figure 3 BD).
[0081] When anti-CD28 and anti-CD154 antibodies were added to the co-culture of antigen-specific / proliferative Treg cells, the percentage of Treg cells showing high expression of the FoxP3 transcription factor increased significantly (t-test difference with / without antibodies: insulin p=0.002, peptide 9-23 p=0.042), as was the case with non-specific / non-proliferative Treg lymphocytes (t-test difference without / with antibodies: insulin p=0.034, trend p=0.063 for peptide 9-23 only).
[0082] Clonality analysis based on Treg lymphocyte TCR library
[0083] Analysis of changes in TCR receptor clonality within the antigen-specific / proliferating Treg lymphocyte population showed that in each culture, the percentage of one to two clones with different TCRβ specificities increased at a time. However, these increases did not exceed a few tens of percent of all proliferating cells ( Figure 4 ).
[0084] Functional test - inhibition of effector T lymphocyte proliferation
[0085] Analysis of the immune response in the proliferation inhibition assay confirmed the suppressive effect of all Treg lymphocyte subsets studied (ANOVA, p<0.05) ( Figure 5 ).
[0086] The efficacy of peptides
[0087] Comparative analysis showed that when the suppressed responders in the experiment were polyclonal effector T cells (ANOVA, F = 8.03 p = 0.047) ( Figure 5 A) and effector T cells specific for the tested antigens (ANOVA, F=20.40p=0.045) ( Figure 5B), the performance of Tregs specific for peptide 9-23 was statistically significantly higher compared to the Tregs specific for insulin used for testing.
[0088] Polyclonal versus specific
[0089] The effectiveness of proliferation inhibition was higher in specific Tregs compared with polyclonal Tregs in all tests, but did not reach statistical significance in any test (ANOVA, p<0.05).
[0090] However, it has been shown that the composition of specific Tregs is mainly responsible for the inhibitory effect in the test. After specific Treg (proliferative) is separated from nonspecific Treg (non-proliferative), compared with nonspecific Treg, specific Treg suppresses significantly more effector T cell reactions. This significance relates to a test in which the respondent is a polyclonal effector T cell (only significant for peptide 9-23: ANOVA, F=8.21p=0.028, for insulin: ANOVA, F=1.31p=0.33), and a test in which the respondent is a specific effector T lymphocyte (for peptide 9-23: ANOVA, F=186.32p=0.005, for insulin: ANOVA, F=22.47p=0.041).
[0091] Functional test - inhibition of interferon secretion
[0092] Analysis of immune responses in the interferon gamma suppression assay confirmed the suppressive effect of all Treg lymphocyte subsets studied (ANOVA, p<0.05) ( Figure 6 and 7 ).
[0093] The efficacy of peptides
[0094] Comparative analysis showed that when the inhibitory responders in the experiment were polyclonal effector T cells, the performance of 9-23 peptide-specific Treg was higher than that of pan-insulin-specific Treg (ANOVA, F=5.78p=0.025)( Figure 6 A and 7). Similar differences were observed when the inhibitory responders in the experiment were specific effector T cells for the test antigen, but the differences did not reach statistical significance (ANOVA, F = 1.86 p = 0.22) ( Figure 6 B and 7).
[0095] Polyclonal versus specific
[0096] Response suppression efficiency was higher in the specific Tregs tested compared to the polyclonal Tregs, but this did not reach statistical significance in any of the tests (ANOVA, p<0.05).
[0097] However, in the case of peptide 9-23 stimulation, it has been shown that in the assay, it is mainly the specific Tregs components that are responsible for the inhibitory effect. After separating specific Treg (proliferative) from nonspecific Treg (non-proliferative), it has been shown that the specific Treg of 9-23 peptides statistically more significantly suppresses effector T cell responses compared to nonspecific Treg. This significance relates to the test in which the responder is a polyclonal effector T cell (ANOVA, F=5.3p=0.031) and the specific effector T cell (ANOVA, F=111.84p=0.0004) of 9-23 peptides.
[0098] When the responder is an effector T cell specific for insulin, a stronger inhibitory effect is also observed in the case of insulin-specific Tregs compared to nonspecific Tregs. The statistical significance of the effect is observed only in some experiments and post-analysis, but the overall analysis proves that it is not statistically significant (ANOVA, F=0.31p=0.56). For polyclonal responders, there is no difference between insulin-specific Tregs and nonspecific Tregs (ANOVA, F=0.0004p=0.94).
[0099] discuss
[0100] The subject of this article is an in vitro method for obtaining antigen-specific regulatory T cells, thereby allowing the clinical use of these cells for the treatment of autoimmune diseases such as: multiple sclerosis, rheumatoid arthritis, type 1 diabetes and for the suppression of unwanted immune responses such as transplant rejection, allergic reactions and graft-versus-host disease (GVHD). Today, regulatory T cells used in therapy are polyclonal, meaning that they recognize many different antigens and their effectiveness can therefore be limited (Marek-Trzonkowska N 2014)(Trzonkowski P 2013)(Marek-Trzonkowska N 2013)(Marek-Trzonkowska N 2012)(Hoffmann P 2009)(Trzonkowski P 2009)(Di Ianni M2011)(Bluestone JA 2015)(Stelmaszczyk-Emmel A 2015)(Vignali DA 2008)(Geem D2015). This approach allows targeting of Treg lymphocytes to tissues expressing specific antigens and to specific autoreactive lymphocytes responsible for inflammatory responses against specific antigens. The use of antigen-specific Tregs will allow more precise treatment and reduction of Treg doses. Therefore, it will increase the effectiveness of treatment and reduce possible side effects.
[0101] The use of such antigen-specific Treg lymphocytes has been described in animal models, and the first attempts to obtain such cells in humans were made a few years ago. Initially, it involved rather induced Treg lymphocytes and Tr1 cells, and then natural Treg lymphocytes. In the case of Treg, these methods are based on the use of naturally occurring antigen-presenting cells or cells appropriately prepared from cell lines presenting specific antigens. Recently, attempts have also been made to modify genes, including the insertion of regulatory receptors into artificial lymphocytes specific for specific antigens (so-called Treg CAR lymphocytes).
[0102] The possibility of antigen-specific regulation of immune responses is important from a therapeutic point of view. Physiologically, the immune system recognizes and destroys foreign and dangerous antigens, while tolerating self-cross-reactions (weavings). However, in the case of autoimmune diseases, such as multiple sclerosis (MS), type 1 diabetes (DM1), psoriasis, systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), this mechanism is impaired (Sénécal V 2015)(Trzonkowski P 2015)(Marek-Trzonkowska N 2012)(Pujol-Autonell I 2013)(Lima XT 2015)(Mu Q 2015)(Orent W 2015). Effector lymphocytes begin to destroy their own organs, perceiving the self-antigens that build their own tissues as foreign. This process leads to irreversible changes. Currently, the treatment of autoimmune diseases is usually simplified to pharmacological immunosuppression and suppression of inflammatory responses. However, over time, such therapies have proven to be ineffective. Despite initial improvement, it is impossible to completely stop the progression of the disease, and its interruption is often associated with an exacerbation of the disease. This treatment is also associated with a severe decrease in immunity (Gupta S 2012). As a result, patients become susceptible to infections, and in patients receiving immunosuppressive drugs, the course of infections is more severe than in healthy people. Nonspecific immunosuppression also increases the risk of cancer development (a higher percentage of cases in patients receiving immunosuppressive drugs) (Andrés A 2005)(Rama I 2010).
[0103] From the perspective of transplantology, the antigen-specific regulation of immune responses is also an important issue. Organ transplantation is often a life-saving operation, but it is associated with the need to constantly take strong immunosuppressive drugs. Discontinuation of treatment is associated with an increased immune response against the transplanted organ tissue, which can lead to its destruction within a short period of time. The use of immunosuppressive drugs, for example in the case of autoimmune diseases, is associated with the occurrence of serious adverse side effects. In addition, some drugs from this group of drugs, while protecting the transplanted organ from the destructive effects of the patient's immune system, at the same time have toxic effects on the graft or other tissues. An example here are the nephrotoxic inhibitors of calcineurin (cyclosporine and tacrolimus) used in kidney transplantation (Prókai 2015) or rapamycin for islet recipients that would impair the action of the transplanted cells (ZhangN1 2006)(Berney 2009). The issue of immunosuppression and regulation of immune responses is also closely related to bone marrow transplantation. The main difference between organ transplantation and bone marrow transplantation is that in the former the drugs try to protect the transplanted organ from the destructive effects of the recipient's immune system, while in the second case there is no risk of transplant rejection, but the transplanted bone marrow is the source of cells that attack the recipient's body and may cause its death (Di Ianni M 2011)(Zhao K 2015). The fight against excessive immune responses, regardless of the source of the immune system cells that attack the patient's body, also reduces the use of nonspecific immunosuppression. In both cases, i.e. allogeneic solid organ transplantation and bone marrow hematopoietic cells, alloantigens are strictly defined as stimulating immune system responses and their effects can be regulated by antigen-specific Treg lymphocytes.
[0104] In this study, we decided to use antigen-loaded monocytes as antigen presenting cells (APCs) to separate antigen-specific regulatory T cells from all polyclonal Tregs in vitro. A schematic diagram of the entire experiment is shown in Figure 1 shown.
[0105] Polyclonal Treg cells with a CD3+CD4+CD25highCD127 phenotype grown with gamma-irradiated autologous monocytes displaying a specific antigen (eg insulin or peptide 9-23 insulin β chain) will proliferate only if they are specific for the antigen presented by the monocytes.
[0106] Many antigens have no affinity for Treg lymphocytes (these cells are immunologically anergic) or may undergo phenotypic changes and lose their regulatory properties during stimulation. Therefore, the conditions under which the co-culture is carried out are important, on the one hand, leading to the proliferation of specific Treg cells and, on the other hand, maintaining their regulatory and suppressive properties. Both conditions are met after adding anti-CD28 and anti-CD154 antibodies to the co-culture, which provides the Treg cells with the missing second signal. In the presence of anti-CD28 and anti-CD154 antibodies, Treg lymphocytes specific for the presented antigen begin to proliferate without losing stability defined as the expression of the FoxP3 factor (it even increases the expression of this factor) and activity in functional suppression ( Figure 5-7 ).
[0107] Pure antigen-specific Tregene lymphocyte populations are sorted using a FACS cell sorter. Sorting is performed under laboratory conditions (Aria IIu sorter, BD Biosciences) or under clean laboratory conditions that allow the production of advanced therapeutic products (INFLUX sorter that complies with Good Manufacturing Practice (GMP) conditions). Sorting is possible due to the pre-staining of polyclonal Treg lymphocytes with fluorescent dyes (CFSE or Violet). Treg cells that proliferate in response to the presence of antigen, i.e., antigen-specific Tregs, begin to dilute / lose fluorescence intensity, which decreases by about half with each subsequent cell division. Based on this change in fluorescence, low-fluorescence proliferating cells (antigen-specific Treg lymphocytes) and high-fluorescence non-proliferative cells (nonspecific Treg lymphocytes) can be separated and sorted ( Figure 2 ). Such sorted cells can be further grown and used for functional testing.
[0108] The proposed method allowed obtaining antigen-specific Treg lymphocytes with a preserved regulatory cell phenotype, as evidenced by the expression of the FoxP3 transcription factor and their activity in functional assays (inhibition of proliferation and suppression of interferon gamma production) was higher than that of the starting polyclonal T-cell population.
[0109] It should be emphasized that the results obtained do not indicate a high clonality of the specific cells obtained. Analysis of the TCR repertoire did not reveal a significant increase in the percentage of Treg lymphocytes expressing a specific class of TCR receptors ( Figure 5 ).
[0110] Compared with polyclonal Treg lymphocytes, the high expression of FoxP3 (FoxP3 High ) can explain the superior suppressive properties of antigen-specific Treg lymphocytes. HighTreg cells are the most active suppressive Treg cell fraction, as their immunomodulatory activity is positively correlated with the expression intensity of the FoxP3 factor (Marek N 2011)(Ryba M2011). Antigen-specific induction of a high percentage of FoxP3 High The fact that they are Treg cells explains the higher therapeutic effect of using such cells. The cells seem to be activated only by a specific antigen and their action is restricted to tissues expressing this antigen. In functional tests, we analyzed the influence of Treg cells on the proliferation and production of interferon gamma (IFN-γ) by effector T lymphocytes. The results obtained showed that, in contrast to polyclonal Treg lymphocytes, antigen-specific Treg lymphocytes tend to suppress the proliferation of Teff lymphocytes and the production of IFN-γ by these cells. Figure 5-7 This suppression refers to polyclonal Teff lymphocytes for the same antigen as the Treg used during the test ( Figure 5 a, 6a, 7) and antigen-specific Teff lymphocytes ( Figure 5 b, 6b, 7). This system is particularly important as it relates to the in vivo situation during disease, where antigen-specific Teff lymphocytes (autoreactive lymphocytes) are primarily responsible for the destruction of tissues or organ rejection in the autoimmune process.
[0111] The fact that the antigen-specific Treg lymphocytes we created are able to suppress specific lymphocytes should have a significant impact on the effectiveness of the treatment.
[0112] in conclusion
[0113] Using this method, we were able to generate antigen-specific regulatory T cells. The monocytes used in the protocol were loaded with specific antigens. A combination of anti-CD28 and anti-CD154 antibodies was used to activate antigen-released autologous monocytes to stimulate the proliferation of antigen-specific Treg lymphocytes.
[0114] Author Contributions
[0115] DI-G, MG, and PT wrote the article. PT designed and planned the experiments. DI-G, MG, and PT performed and analyzed the experiments.
[0116] funds
[0117] This work was supported by the Polish National Research and Development Centre:
[0118] LIDER / 160 / L-6 / 14 / NCBR / 2015 and STRATEGMED1 / 233368 / 1 / NCBR / 2014 and Polish Ministry of Infrastructure Project: POIR.01.01.01-00-0769 / 15-01 of PolTreg SA
[0119] abbreviation
[0120] A FACTT, a European network initiative to focus and accelerate cell-based tolerance-inducing therapies; Ag, antigen; APC, antigen-presenting cell; CFSE, carboxyfluorescein diacetate succinimidyl ester; COST, European Committee for Cooperation in Science and Technology; ELISA, enzyme-linked immunosorbent assay; ELISpot, enzyme-linked immunospot; IFN-γ, interferon gamma; INS, insulin; Mo, monocyte; NON, nonproliferative (nonspecific); PBMC, peripheral blood mononuclear cell; POLY, polyclonal; p / s, penicillin-streptomycin; PRO, proliferative (antigen-specific); Treg, regulatory T cell; Teff, effector T cell (responder); T1D, type 1 diabetes
[0121] References
[0122] Andrés A(2005)."Cancer incidence after immunosuppressive treatment following kidney transplantation." Crit Rev Oncol Hematol 56(1):71-85.
[0123] Barbaro MP, Spanevello A, Palladino GP, Salerno FG, Lacedonia D, Carpagnano GE, (2014). "Exhaled matrix metalloproteinase-9(MMP-9) in different biological phenotypes of asthma." Eur J Intern Med 25(1):92-96.
[0124] Berney T,Secchi A(2009)."Rapamycin in island transplantation: friend or foe?" Transpl Int 22(2):153-161.
[0125] Bluestone JA,Buckner JH,Fitch M,Gitelman SE,Gupta S,Hellerstein MK,Herold KC,Lares A,Lee MR,Li K,Liu W,Long SA,Masiello LM,Nguyen V,Putnam AL,Rieck M,Sayre PH,Tang Q,(2015).“Type 1 diabetes immunotherapy using polyclonal regulatory T cells.” Sci Transl Med 7(315):315ra189.
[0126] Bluestone JA,Trotta E,Xu D,(2015).“The therapeutic potential of regulatory T cells for the treatment of autoimmune disease.” Expert Opin Ther Targets 19(8):1091-1103.
[0127] By Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF, (2011). "Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation." Blood 117(14):3921-398.
[0128] Fontenot JD, Gavin MA, Rudensky AY, (2003).."Foxp3 programs the development and function of CD4+CD25+regulatory T cells." Nat Immunol4(4):330-336.
[0129] Gambineri E,Torgerson TR,Ochs HD,(2003)."Immune dysregulation,polyendocrinopathy,enteropathy,and X-linked inheritance(IPEX),a syndrome ofsystemic autoimmunity caused by mutations of FOXP3,a critical regulator of T-cell homeostasis." Curr Opin Rheumatol 15:430-435.
[0130] Geem D,Harusato A,Flannigan K,Denning TL,(2015)."Harnessingregulatory T cells for the treatment of inflammatory bowel disease." Inflamm Bowel Dis 21(6):1409-1418.
[0131] Gupta S,(2012)."Immunotherapies in diabetes mellitus type 1." Med Clin North Am 96(3):621-634.
[0132] Hoffmann P,Boeld TJ,Eder R,Huehn J,Floess S,Wieczorek G,Olek S,Dietmaier W,Andreesen R,Edinger M,(2009)."Loss of FOXP3 expression in naturalhuman CD4+CD25+regulatory T cells upon repetitive in vitro stimulation." Eur J Immunol 39(4):1088-1097.
[0133] Krzystyniak A, K,Witkowski P,Trzonkowski P,(2014)."Islet celltransplant and the incorporation of Tregs." Curr Opin Organ Transplant 19(6):610-615.
[0134] Lima XT,Cintra ML,Piaza AC,Mamoni RL,Oliveira RT, RF,BlottaMH,(2015)."Frequency and characteristics of circulating CD4(+)CD28(null)Tcells in patients with psoriasis." Br J Dermatol 173(4):998-1005.
[0135] Malek TR(2003)."The main function of IL-2 is to promote thedevelopment of T regulatory cells." J Leukoc Biol 74(6):961-965.
[0136] Malek TR,Castro I(2010)."Interleukin-2 receptor signaling:at theinterface between tolerance and immunity." Immunity 33(2):153-165.
[0137] Marek-Trzonkowska N,Mysliwiec M,Dobyszuk A,Grabowska M,Techmanska I,Juscinska J,Wujtewicz MA,Witkowski P,Mlynarski W,Balcerska A,Mysliwska J,Trzonkowski P,(2012)."Administration of CD4+CD25highCD127-regulatory T cellspreservesβ-cell function in type 1 diabetes in children." Diabetes Care35(9):1817-1820.
[0138] Marek-Trzonkowska N, M, Siebert J, Trzonkowski P, (2013). "Clinical application of regulatory T cells in type 1 diabetes." Pediatr Diabetes 14(5):322-332.
[0139] Marek-Trzonkowska N, M, Dobyszuk A, Grabowska M, Derkowska I, J, Owczuk R, Szadkowska A, Witkowski P, W,Jarosz-Chobot P,Bossowski A,Siebert J,Trzonkowski P,(2014)."Therapy of type 1 diabetes withCD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic lesions-results of one year follow-up." Clin Immunol 153(1):23-30.
[0140] Marek N, Bieniaszewska M, Krzysztof A, J, J,WitkowskiP,Hellmann A,Trzonkowski P,(2011)."The time is crucial for ex vivo expansion of T regulatory cells for therapy." Cell Transplant 20(11-12):1747-1758.
[0141] Martelli MF,Di Ianni M,Ruggeri L,Falzetti F,Carotti A,Terenzi A,Pierini A,Massei MS,Amico L,Urbani E,Del Papa B,Zei T,Iacucci Ostini R,Cecchini D,Tognellini R,Reisner Y,Aversa F,Falini B,Velardi A,(2014)."HLAhaploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse." Blood 124(4):638-644.
[0142] Mu Q, Zhang H, Luo XM, (2015). "SLE: another autoimmune disorder influenced by microbes and diet?" Front Immunol 6( 608):1-10.
[0143] Nishimura E, Sakihama T, Setoguchi R, Tanaka K, Sakaguchi S, (2004). "Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+regulatory Tcells." Int Immunol 16(8):1189-1201.
[0144] Orent W,McHenry AR,Rao DA,White C,Klein HU,Bassil R,Srivastava G,Replogle JM,Raj T,Frangieh M,Cimpean M,Cuerdon N,Chibnik L,Khoury SJ,CarlsonEW,Brenner MB,De Jager P,EmBradshaw,EMBER W,(2015)."Rheumatoid arthritis-associated RBPJ polymorphism alters memory CD4+ T cells." Hum Mol Genet DOI:10.1093 / hmg / ddv474.
[0145] Panettieri RA,Jr Covar R,Grant E,Hillyer EV,Bacharier L,(2008)."Natural history of asthma:persistence versus progression-does the beginningpredict the end?" J Allergy Clin Immunol 121(3):607-613.
[0146] Procai Csohány R,Sziksz E,Pap D,Balicza-Himer L,Boros S,Magda B,Vannay Kis-Petik K,Fekete A,Peti-Peterdi J,SzabóAJ,(2015)."Calcineurin-inhibition results in upregulation of local renin and subsequent vascularendothelial growth factor production in renal collecting ducts." Transplantation DOI:10.1097 / TP.000000000000961.
[0147] Pujol-Autonell I,Ampudia RM,Monge P,Lucas AM,Carrascal J,Verdaguer J,Vives-Pi M,(2013)."Immunotherapy with Tolerogenic Dendritic Cells Alone or inCombination with Rapamycin Does Not Reverse Diabetes in NOD Mice." ISRN Endocrinol 2013(ID 346987):1-5.
[0148] Rama I,GrinyóJM(2010)."Malignancy after renal transplantation:therole of immunosuppression." Nat Rev Nephrol 6(9):511-519.
[0149] Ryba M,Marek N,Hak Rybarczyk-Kapturska K, M,Trzonkowski P, J,(2011)."Anti-TNF rescue CD4+Foxp3+regulatory T cells in patientswith type 1 diabetes from effects mediated by TNF." Cytokine 55(3):353-361.
[0150] Sénécal V,Deblois G,Beauseigle D,Schneider R,Brandenburg J,NewcombeJ,Moore CS,Prat A,Antel J,Arbour N,(2015)."Production of IL-27 in multiplesclerosis lesions by astrocytes and myeloid cells:Modulation of local immuneresponses." Glia DOI:10.1002 / glia.22948.
[0151] Stelmaszczyk-Emmel A(2015)."Regulatory T cells in children withallergy and asthma:it is time to act." Respir Physiol Neurobiol 209:59-63.
[0152] Tang Q,Bluestone JA(2013)."Regulatory T-cell therapy intransplantation-moving to the clinic." Cold Spring Harb Perspect Med 3(11):pii:a015552.
[0153] Trzonkowski P,Bacchetta R,Battaglia M,Berglund D,Bohnenkamp HR,tenBrinke A,Bushell A,Cools N,Geissler EK,Gregori S,Marieke van Ham S,Hilkens C,Hutchinson JA,Lombardi G,Madrigal JA,Marek-Trzonkowska N,Martinez-Caceres EM,Roncarolo MG,Sanchez-Ramon S,Saudemont A,Sawitzki B,(2015)."Hurdles intherapy with regulatory T cells." Sci Transl Med 7(304):304ps18.
[0154] Trzonkowski P,Bieniaszewska M, J,Dobyszuk A,Krzystyniak A,MarekN, J,Hellmann A,(2009)."First-in-man clinical results of thetreatment of patients with graft versus host disease with human ex vivoexpanded CD4+CD25+CD127-T regulatory cells." Clin Immunol 133(1):22-26.
[0155] Trzonkowski P,Dukat-Mazurek A,Bieniaszewska M,Marek-Trzonkowska N,Dobyszuk A, J,Dutka M, J,Hellmann A,(2013)."Treatment of graft-versus-host disease with naturally occurring T regulatory cells." BioDrugs 27(6):605-614.
[0156] Trzonkowski P,Szaryńska M, J, A,(2009)."Ex vivoexpansion of CD4(+)CD25(+)T regulatory cells for immunosuppressive therapy." Cytometry A 75(3):175-188.
[0157] Vignali DA,Collison LW,Workman CJ,(2008)."How regulatory T cellswork." Nat Rev Immunol 8(7):523-532.
[0158] Wang YM,Zhang GY,Wang Y,Hu M,Wu H,Watson D,Hori S,Alexander IE,HarrisDC,Alexander SI,(2006)."Foxp3-transduced polyclonal regulatory T cellsprotect against chronic renal injury from adriamycin." J Am Soc Nephrol 17(3):697-706.
[0159] Xiao F,Ma L,Zhao M,Huang G,Mirenda V,Dorling A,Lechler R,Lombardi G,(2014)."Ex vivo expanded human regulatory T cells delay islet allograftrejection via inhibiting islet-derived monocyte chemoattractant protein-1production in CD34+stem cells-reconstituted NOD-scid IL2rγnull mice." PLoS One.2014 Mar 3;9(3):e90387. 9(3)::e9038.
[0160] Yi S,Ji M,Wu J,Ma X,Phillips P,Hawthorne WJ,O'Connell PJ,(2012)."Adoptive transfer with in vitro expanded human regulatory T cells protectsagainst porcine islet xenograft rejection via interleukin-10 in humanizedmice." Diabetes 61(5):1180-1191.
[0161] Zhang N,Su D,Qu S,Tse T,Bottino R,Balamurugan AN,Xu J,Bromberg JS,Dong HH,(2006)."Sirolimus is associated with reduced islet engraftment andimpaired beta-cell function." Diabetes 55(9):2429-2436.
[0162] Zhao K,Ruan S,Yin L,Zhao D,Chen C,Pan B,Zeng L,Li Z,Xu K,(2015)."Dynamic regulation of effector IFN-γ-producing and IL-17-producing T cellsubsets in the development of acute graft-versus-host disease." Mol Med Rep 2016 Feb;13(2):1395-403.
Claims
1. A method for preparing antigen-specific T lymphocytes labeled and sorted with a monoclonal antibody, wherein: The lymphocytes: a) by using autologous CD14+ monocytes loaded with antigen; b) suspending the regulatory T lymphocytes or effector T lymphocytes to be produced in PBS and staining the cells with a fluorescent dye; c) then incubating the lymphocytes in the dark; d) The lymphocytes are then vigorously washed several times with culture medium; e) suspending regulatory T lymphocytes or effector T lymphocytes stained with an intracellular fluorescent dye and gamma-irradiated autologous CD14+ monocytes loaded with antigen in a culture medium, wherein the autologous CD14+ monocytes are gamma-irradiated under standard conditions for irradiating blood products; f) incubating the co-culture of regulatory T lymphocytes or effector T lymphocytes and CD14+ monocytes with anti-CD154 and anti-CD28 antibodies; g) incubating the co-culture in a culture medium; and h) After incubation, antigen-specific T lymphocytes are sorted based on low-intensity intracellular dye fluorescence, which is a marker for antigen specificity, since loss of fluorescence correlates with proliferation intensity.
2. The method according to claim 1, characterized in that The regulatory T lymphocytes or effector T lymphocytes are suspended at the following concentrations: 1×10 6 cells / ml PBS.
3. The method according to claim 1, characterized in that The lymphocytes were stained with one of the following fluorescent dyes: CFSE or Violet Blue at a final concentration of 1-5 μM.
4. The method according to claim 1, characterized in that The lymphocytes were incubated at room temperature or 37°C for 20 minutes.
5. The method according to claim 1, characterized in that The autologous CD14+ monocytes were added to the co-culture at a final ratio of 1:1 autologous CD14+ monocytes:lymphocytes.
6. The method according to claim 1, characterized in that The co-culture of autologous CD14+ monocytes and lymphocytes was incubated with anti-CD154 antibody at a final concentration of 5 μg / ml and anti-CD28 antibody at a final concentration of 5 μg / ml.
7. The method according to claim 1, characterized in that The co-cultures were incubated at 37°C in 5% CO2.
8. The method according to claim 1, characterized in that Specificity for the antigen is assessed in a functional test in which antigen-specific T lymphocytes are more active than nonspecific T lymphocytes, wherein in the case of regulatory T lymphocytes activity is defined as inhibition of effector T lymphocyte function, and in the case of effector T lymphocytes activity is defined as increased proliferation intensity and increased production intensity of cytokines and cytotoxic factors.
9. The method according to claim 8, characterized in that The antigen-specific T lymphocytes are T lymphocytes sorted based on low fluorescence of intracellular dyes.
10. The method according to claim 8, characterized in that The non-specific T lymphocytes are T lymphocytes sorted based on the high fluorescence of the retained intracellular dye.
